NCT06462287View on ClinicalTrials.gov

EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

April 19, 2026

Study Completion Date

April 19, 2026

Conditions
Apnea, Obstructive
Interventions
DRUG

Aprepitant 125 and 80Mg Oral Capsule

Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)

DRUG

Placebo

Placebo:1 oral capsule time a day for 4 days

Trial Locations (1)

76000

RECRUITING

CHU de Rouen, Rouen

All Listed Sponsors
lead

University Hospital, Rouen

OTHER